Key Points
- Asif Ali, CFO, sold 1,750 shares on April 20 at $105.47 apiece for $184,572.50 to cover tax withholding on vested awards; he now directly owns 59,003 shares, a 2.88% decline in his stake.
- Ali previously executed larger insider sales this year — 24,765 shares on March 26 (~$2.58M) and 46,203 shares on January 27 (~$3.84M) — signaling substantial insider liquidations over recent months.
- Protagonist recently missed quarterly expectations (EPS -$0.69 vs. -$0.53 est., revenue $7.44M vs. $14.92M), trades near its 1‑year high with a $6.76B market cap, and holds a consensus analyst rating of "Moderate Buy" with a $108.15 target.
Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) CFO Asif Ali sold 1,750 shares of Protagonist Therapeutics stock in a transaction on Monday, April 20th. The shares were sold at an average price of $105.47, for a total transaction of $184,572.50. Following the completion of the sale, the chief financial officer directly owned 59,003 shares of the company's stock, valued at approximately $6,223,046.41. This trade represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Asif Ali also recently made the following trade(s):
- On Thursday, March 26th, Asif Ali sold 24,765 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $104.24, for a total transaction of $2,581,503.60.
- On Tuesday, January 27th, Asif Ali sold 46,203 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $83.13, for a total transaction of $3,840,855.39.
Protagonist Therapeutics Trading Up 0.4%
PTGX opened at $105.89 on Wednesday. The company has a fifty day moving average price of $95.92 and a two-hundred day moving average price of $87.50. The company has a market cap of $6.76 billion, a P/E ratio of -51.65 and a beta of 2.12. Protagonist Therapeutics, Inc. has a 1-year low of $41.28 and a 1-year high of $107.84.
Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last posted its earnings results on Wednesday, February 25th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.16). The business had revenue of $7.44 million for the quarter, compared to the consensus estimate of $14.92 million. Protagonist Therapeutics had a negative return on equity of 19.89% and a negative net margin of 282.83%. On average, research analysts forecast that Protagonist Therapeutics, Inc. will post 1.02 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research firms have recently commented on PTGX. Leerink Partners boosted their target price on shares of Protagonist Therapeutics from $107.00 to $110.00 and gave the stock an "outperform" rating in a research report on Thursday, March 19th. Jefferies Financial Group reissued a "buy" rating and set a $121.00 target price on shares of Protagonist Therapeutics in a research report on Wednesday, March 18th. The Goldman Sachs Group upped their price objective on shares of Protagonist Therapeutics from $65.00 to $95.00 and gave the stock a "neutral" rating in a research report on Tuesday, March 3rd. Citigroup upped their price objective on shares of Protagonist Therapeutics from $115.00 to $125.00 and gave the stock a "buy" rating in a research report on Thursday, March 19th. Finally, Truist Financial upped their price objective on shares of Protagonist Therapeutics from $110.00 to $121.00 and gave the stock a "buy" rating in a research report on Tuesday, April 14th. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Protagonist Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $108.15.
View Our Latest Stock Report on Protagonist Therapeutics
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Louisiana State Employees Retirement System purchased a new position in Protagonist Therapeutics in the first quarter valued at about $2,751,000. Rockefeller Capital Management L.P. boosted its stake in Protagonist Therapeutics by 10.5% in the fourth quarter. Rockefeller Capital Management L.P. now owns 3,292 shares of the company's stock valued at $288,000 after acquiring an additional 312 shares during the last quarter. Seven Fleet Capital Management LP purchased a new position in Protagonist Therapeutics in the fourth quarter valued at about $699,000. Invesco Ltd. boosted its stake in Protagonist Therapeutics by 56.2% in the fourth quarter. Invesco Ltd. now owns 1,567,840 shares of the company's stock valued at $136,935,000 after acquiring an additional 564,134 shares during the last quarter. Finally, KVP Capital Advisors LP purchased a new position in Protagonist Therapeutics in the fourth quarter valued at about $4,629,000. 98.63% of the stock is currently owned by hedge funds and other institutional investors.
About Protagonist Therapeutics
(
Get Free Report)
Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist's approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.
Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn's disease.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
